#USA #Phoenix #MolecuLight #fluorescence imaging #Burn Care

Revolutionizing Burn Care with Advanced Imaging Technology

MolecuLight Inc. has made a significant impact in the field of burn care, presenting groundbreaking innovations at the recent American Burn Association (ABA) Annual Meeting held from April 8 to 11, 2025, in Phoenix, Arizona. The company, recognized globally as a pioneer in point-of-care fluorescence imaging, showcased its state-of-the-art systems designed to detect bacteria in wounds rapidly and effectively.

Breakthrough Presentations from Leading Surgeons

One of the highlights from the event was Dr. Erik Hanson-Viana, a prominent plastic and reconstructive surgeon from Hospital Angeles in Mexico. He delivered a compelling presentation titled "Fluorescence Imaging-Guided Sampling Provides More Accurate and Actionable Microbiology Compared to the Levine Technique." Scheduled for April 9 at 11:45 AM during one of the Educational Forums, Dr. Hanson-Viana discussed how the use of MolecuLight’s imaging technology is transforming the reconstruction approach for patients with severe burns. His results indicated that this innovative method enables practitioners to identify the optimal timing and site for grafts, surpassing conventional techniques that have been widely used in previous years.

In another session, Dr. Carlos Daniel Torres García, a research resident in plastic surgery at the same hospital, presented his award-winning research focusing on bacterial fluorescence signals within dermal regeneration template infections among burn patients. His findings highlighted the critical relationship between bacterial loads detected by MolecuLight technology and the failures linked to cellular tissue products during burn reconstruction. Dr. García's research has gained international acclaim, securing second place for best scientific protocol at the 55th Annual Mexican Congress of Plastic Surgery held earlier this year.

Live Demonstrations of Innovative Technology

Visitors to the conference had the opportunity to engage directly with the experts and witness live demonstrations of MolecuLight’s imaging systems—the MolecuLight iX® and MolecuLight DX™. Located at booth #626 throughout the duration of the event, these demonstrations allowed attendees to observe how real-time biological load assessments can inform clinical decisions and enhance burn care.

Dr. Hanson-Viana was enthusiastic about the implications of real-time bacterial visualization provided by MolecuLight technologies. He stated, "The ability to see bacteria as it occurs has profound implications for improving the outcomes of burn reconstruction. By providing immediate and actionable insights, MolecuLight facilitates more precise interventions, ultimately bettering the results for our patients. My research illustrates the clear advantage of targeted sampling using MolecuLight over traditional methods, and I am excited to share these findings with my colleagues at the ABA meeting."

About MolecuLight Inc.

MolecuLight Corp. is a private company specializing in medical imaging technologies tailored for wound care. The firm's flagship imaging devices, MolecuLight iX® and DX™, are the only point-of-care imaging devices approved by the FDA that can detect elevated bacterial loads in wounds in real-time. These technologies provide precise digital wound measurements and comprehensive support for wound management, backed by robust clinical evidence and over a hundred peer-reviewed publications.

With innovations like these, MolecuLight aims not only to enhance treatment for patients suffering from burns but to set a new standard in the medical imaging arena, particularly in the field of wound care. For more information on MolecuLight and its impactful technologies, please visit MolecuLight’s official website.